Tivozanib hydrochloride hydrate

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Tivozanib hydrochloride hydrate 是一种有效的、选择性的、具有口服活性的VEGFR 酪氨酸激酶 抑制剂，对 VEGFR-1、VEGFR-2、VEGFR-3的 IC50 值分别为 0.21、0.16、0.24 nM。Tivozanib hydrochloride hydrate 抑制肿瘤组织中的血管生成和血管通透性，并显示出抗肿瘤活性。Tivozanib hydrochloride hydrate 具有研究转移性肾细胞癌 (RCC) 的潜力。

Tivozanib hydrochloride hydrate is a selective and orally activeVEGFR tyrosine kinase inhibitor with IC50 of 0.21, 0.16, 0.24 nM for VEGFR-1, VEGFR-2, VEGFR-3, respectively. Tivozanib hydrochloride hydrate inhibits angiogenesis and vascular permeability in tumor tissues and shows antitumor activity. Tivozanib hydrochloride hydrate has the potential for the research of metastatic renal cell carcinoma (RCC).

Tivozanib hydrochloride hydrate inhibits the phosphorylation of VEGFR-1, VEGFR-2 and VEGFR-3.

Tivozanib hydrochloride hydrate (1 mg/kg; p.o.; 14 days) suppresses the development of CNV lesions and leds to a significant regression of established CNV, reducing the affected areas by 67.7%.

——

Angiogenesis

VEGFR

VEGFR

——

——

682745-41-1

509.34

C22H22Cl2N4O6

>98% (HPLC)

In Vitro:?DMSO 中的溶解度 : 250 mg/mL (490.83 mM; 超声助溶 )

O.Cl.COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC

——

(-20℃)

With Ice Pack

≥ 2 years